Precision BioSciences shares are trading higher after the company announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD.

Precision BioSciences

Precision BioSciences

DTIL

0.00

Precision BioSciences shares are trading higher after the company announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD.